Status:
COMPLETED
Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Myelofibrosis
Eligibility:
All Genders
18+ years
Brief Summary
The investigators would like to conduct a retrospective study in five centers in France in the goal to evaluate the survival of patients receiving allogeneic hematopoietic stem cell transplantation fo...
Detailed Description
The allogeneic stem cell transplantation is the only curative treatment for myelofibrosis. However, because of complications such as infection, graft-versus-host disease and conditioning toxicity, thi...
Eligibility Criteria
Inclusion
- adult patients receiving allogeneic hematopoietic stem cell transplantation for myelofibrosis in five centers in France (Nancy, Besancon, Strasbourg, Pitie Salpetriere and Lyon) between 2007 and 2017
- \-
Exclusion
- age \< 18 years old
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2020
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT04282421
Start Date
January 1 2007
End Date
February 1 2020
Last Update
March 12 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.